A molecular model of agonist and nonpeptide antagonist binding to the human V1 vascular vasopressin receptor

Journal of Pharmacology and Experimental Therapeutics

Volumn 294, Issue 1, 2000, Pages 195-203

  Thibonnier, Marc ^a   Coles, Patrick ^a   Conarty, Doreen M ^a   Plesnicher, Christine L ^b   Shoham, Menachem ^a  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

1 [1 [4 (3 ACETAMIDOPROPOXY)BENZOYL] 4 PIPERIDYL] 1,2,3,4 TETRAHYDRO 2 QUINOLINONE; ARGIPRESSIN; OXYTOCIN; RELCOVAPTAN; VASOPRESSIN RECEPTOR;

AMINO ACID SEQUENCE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; BLOOD VESSEL TONE; CELL DIFFERENTIATION; CELL GROWTH; DRUG POTENCY; FETUS; HYDROGEN BOND; HYDROPHOBICITY; NONHUMAN; OSMOLALITY; PRIORITY JOURNAL; RECEPTOR BINDING; SEQUENCE HOMOLOGY; SITE DIRECTED MUTAGENESIS;

AMINO ACID SEQUENCE; ANIMALS; ARGININE VASOPRESSIN; HUMANS; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; MUTAGENESIS, SITE-DIRECTED; PIPERIDINES; QUINOLONES; RADIOLIGAND ASSAY; RATS; RECEPTORS, VASOPRESSIN;

EID: 0033933817     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (39)

1. Birnbaumer M, Seibold A, Gilbert S, Ishido M, Barberis C, Antaramian A, Brabet P and Rosenthal W (1992) Molecular cloning of the receptor for human antidiuretic hormone. Nature (Lond) 367:333-335.
2. Brünger AT (1993) X-PLOR, Version 3.1 Manual: A System for X-Ray Crystallography and NMR. Yale University Press, New Haven, CT.
3. Cotte N, Balestre MN, Phalipou S, Hibert M, Manning M, Barberis C and Mouillac B (1998) Identification of residues responsible for the selective binding of peptide antagonists and agonists in the V2 vasopressin receptor. J Biol Chem 273:29462-29468.
4. 3-pituitary vasopressin receptor. FEBS Lett 356:215-220.
5. 2[8-lysine]vasopressin and oxytocin receptors from a pig kidney cell line. Ear J Biochem 215:1-7.
6. Henderson R, Baldwin JM, Ceska TA, Zemlin F, Beckmann E and Downing KH (1990) Model for the structure of bacteriorhodopsin based on high-resolution electron cryo-microscopy. J Mol Biol 213:899-929.
7. Hibert M, Hoflack J, Trumpp-Kallmeyer S, Mouillac B, Chini B, Mahé E, Cotte N, Jard S, Manning M and Barberis C (1999) Functional architecture of vasopressin/ oxytocin receptors. J Recept Signal Transduct Res 19:589-596.
8. Howl J and Wheatley M (1996) Molecular recognition of peptide and non-peptide ligands by the extracellular domains of neurohypophysial hormone receptors. Biochem J 317:577-582.
9. Hutchins AM, Phillips PA, Venter DJ, Burrell LM and Johnston CI (1995) Molecular cloning and sequencing of the gene encoding a sheep arginine vasopressin type 1a receptor. Biochem Biophys Acta 1263:266-270.
10. Ji TH, Grossmann M and Ji I (1998) G protein-coupled receptors. J Biol Chem 273:17299-17302.
11. Jones TA, Zou JY, Cowan SW and Kjeldgaard M (1991) Improved methods for building protein models in electron density maps and the location of errors in these models. Acta Crystallogr A 47:110-119.
12. Kimura T, Tanizawa O, Mori K, Brownstein MJ and Okayama H (1992) Structure and expression of a human oxytocin receptor. Nature (Lond) 356:526-529.
13. Levitt M (1992) Accurate modeling of protein conformation by automatic segment matching. J Mol Biol 226:507-533.
14. 2 receptor and possible link to nephrogenic diabetes insipidus. Nature (Lond) 357:336-339.
15. 8]vasotocin receptors from teleost fish and toad. Proc Natl Acad Sci USA 91:1342-1345.
16. Manning M, Cheng LL, Stoev S, Sawyer WH, Tribollet E, Barberis C, Wo NC and Chan WY (1995) Novel potent and selective antagonists and radioiodinated ligands for oxytocin and vasopressin receptors, in Neurohypophysis: Recent Progress of Vasopressin and Oxytocin Research (Saito T, Kurokawa K and Yoshida S eds) pp 21-38, Elsevier, Amsterdam.
17. 1a vasopressin receptor fragments interfere with vasopressin binding via specific interaction with the receptor. J Biol Chem 272:21027-21036.
18. 1a arginine vasopressin receptor. Nature (Lond) 356:523-526.
19. 1a receptor. J Biol Chem 270:25771-25777.
20. Oldziej S, Ciarkowski J, Liwo A, Shenderovich MD and Grzonka Z (1995) Conformational aspects of differences in requirements for oxytocin and vasopressin receptors. J Recept Signal Transduct Res 15:703-713.
21. 1a vasopressin receptor with a photoactivable linear peptide antagonist. J Biol Chem 272:26536-26544.
22. 2 vasopressin receptor. J Biol Chem 271:31593-31601.
23. Rodriguez R, Chinea G, Lopez N, Pons T and Vriend G (1998) Homology modelling, model and software evaluation: Three related sources. CABIOS 14:523-528.
24. Rose JP, Wu CK, Hsiao CD, Breslow E and Wand BC (1996) Crystal structure of the neurophysin-oxytocin complex. Nat Struct Biol 3:163-169.
25. Serradeil-Le Gal C, Lacour C, Valette G, Garcia G, Foulon L, Galindo G, Bankir L, Pouzet B, Guillon G and Barberis C (1996) Characterization of SR-121463A, a highly potent and selective, orally active vasopressin V2 receptor antagonist. J Clin Invest 98:2729-2738.
26. Serradeil-Le Gal C, Wagnon J, Guillon G, Garcia C, Lacour C, Cantau B, Guiraudou P, Christophe B, Barberis C, Villanova G, Nisato D, Maffrand JP, Jard S and Le Fur G (1993) Biochemical and pharmacological properties of SR49059, a new potent, non-peptide antagonist of rat and human vasopressin Via receptors. J Clin Invest 92:224-231.
27. Sobolev V, Wade RC, Vriend G and Edelman M (1996) Molecular docking using surface complementarity. Prot Struct Funct Genet 25:120-129.
28. Sugimoto T, Saito M, Mochizuki S, Watanabe Y, Hashimoto S and Kawashima H (1994) Molecular cloning and functional expression of a cDNA encoding the human V1b vasopressin receptor. J Biol Chem 269:27088-27092.
29. Thibonnier M (1993) Antidiuretic hormone: Regulation, disorders, and clinical evaluation in neuroendocrinology, in Concepts in Neurosurgery (Selman W ed) pp 19-30 Williams & Wilkins, Baltimore.
30. Thibonnier M (1998) Development and therapeutic indications of orally-active nonpeptide vasopressin receptor antagonists. Exp Opin Invest Drugs 7:729-740.
31. 1a vasopressin receptor. J Biol Chem 269:3304-3310.
32. 3-pituitary AVP, and oxytocin receptors, in Progress in Brain Research (Urban IJA, Burbach JPH and De Wied D eds) pp 143-158, Elsevier Science BV, Amsterdam.
33. Thibonnier M, Conarty DM, Preston JA, Wilkins PL, Berti-Mattera LN and Mattera R (1998b) Molecular pharmacology of human vasopressin receptors, in Vasopressin and Oxytocin: Molecular, Cellular, and Clinical Advances (Zingg H, Bourque CW and Bichet D eds) pp 251-276, Plenum Press, New York.
34. Thibonnier M, Preston J, Conarty D, Plesnicher C and Berti-Mattera L (2000) Role of the C-terminus region of the human V1-vascular vasopressin receptor in signal transduction (Abstract). Experimental Biology 99 meeting; 1999 April 17-21; Washington, DC, in press.
35. Thibonnier M and Roberts JM (1985) Characterization of human platelet vasopressin receptors. J Clin Invest 76:1857-1864.
36. Van Biesen T, Luttrell LM, Hawes BE and Lefkowitz RJ (1996) Mitogenic signaling via G protein-coupled receptors. Endocr Rev 17:698-714.
37. Vriend G (1990) A molecular modeling and drug design program. J Mol Graph 8:52-56.
38. 1 receptor antagonist. Science (Wash DC) 252:572-574.
39. 2-receptor antagonist. Br J Pharmacol 105:787-792.